RCS - Faron Pharma. Oy - Faron to Participate at Canaccord Conference

Faron Pharmaceuticals OyAnnouncement

02/08/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230802:nRSB9675Ha&default-theme=true

RNS Number : 9675H  Faron Pharmaceuticals Oy  02 August 2023

Faron Pharmaceuticals Ltd.

("Faron" or "the Company")

 

 Faron to Participate in Fireside Chat at the Canaccord Genuity 43rd Annual
Growth Conference

 

Press release, August 02, 2023

 

·    Management to present on Thursday, August 10 at 12:30-12:55 PM
Eastern Time at the InterContinental Boston Hotel in Boston, Massachusetts

·    Presentation will highlight recent updated positive Phase I/II BEXMAB
data of bexmarilimab in relapsed/refractory AML and MDS

 

TURKU, Finland / BOSTON, Massachusetts - Faron Pharmaceuticals Ltd. (AIM:
FARN, First North: FARON), a clinical-stage biopharmaceutical company focused
on tackling cancers via novel immunotherapies, today announces that the
Company's Chief Executive Officer, Dr. Markku Jalkanen, and Chief Medical
Officer, Dr. Marie-Louise Fjällskog, will participate in a fireside chat at
the Canaccord Genuity 43rd Annual Growth Conference on Thursday, August 10,
2023 at 12:30-12:55 PM Eastern Time at the InterContinental Boston Hotel in
Boston, Massachusetts, in Room Abigail Adams C.

 

The Company will discuss the most recent positive clinical data from the
Company's ongoing Phase I/II BEXMAB study, investigating bexmarilimab, Faron's
wholly owned immunotherapy asset, in combination with standard of care (SoC)
in the aggressive hematological malignancies of r/r acute myeloid leukemia
(AML) and myelodysplastic syndromes (MDS). The updated BEXMAB data support
advancement to Phase II in H2 2023 focusing on SoC relapsed/refractory AML and
MDS patients failing hypomethylating agents (HMA). The Company's filing of its
first Biologics License Application (BLA) to the FDA is planned for H1 2025.

 

A live webcast of the fireside chat can be found here
(https://eur01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwsw.com%2Fwebcast%2Fcanaccord89%2Ffarn.l%2F2742223&data=05%7C01%7C%7C97eb49f7492740538efb08db91f2dfef%7Ca2d9b7a432f64a96b03727499230d5fd%7C1%7C0%7C638264244553616816%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000%7C%7C%7C&sdata=7OHAefpzhknjS%2BFg0NxCefxFmORUBQzaVcMkMeAj3Mo%3D&reserved=0)
and in the Investor Relations section of Faron's website at
https://www.faron.com/investors/results-presentations
(https://eur01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.faron.com%2Finvestors%2Fresults-presentations&data=05%7C01%7C%7C97eb49f7492740538efb08db91f2dfef%7Ca2d9b7a432f64a96b03727499230d5fd%7C1%7C0%7C638264244553616816%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000%7C%7C%7C&sdata=Hry%2BtycC1NCGwcGzOgpVG%2FaEo5D6UhZQa8qtHXiv8o0%3D&reserved=0)
. Following the completion of the event, a webcast replay of the fireside chat
will be available on the website for 90 days.

 

For more information please contact:

 

Investor Contact

 

LifeSci Advisors

Daniel Ferry

Managing Director

daniel@lifesciadvisors.com (mailto:daniel@lifesciadvisors.com)

+1 (617) 430-7576

 

Media Contact

 

Faron Pharmaceuticals

Jennifer C. Smith-Parker

Head of Communications

Jennifer.Smith-Parker@faron.com (mailto:Jennifer.Smith-Parker@faron.com)

 

Cairn Financial Advisers LLP, Nomad

Sandy Jamieson, Jo Turner

Phone: +44 (0) 207 213 0880

 

Peel Hunt LLP, Broker

Christopher Golden, James Steel

Phone: +44 (0) 20 7418 8900

 

Sisu Partners Oy, Certified Adviser on Nasdaq First North

Juha Karttunen

Phone: +358 (0)40 555 4727

Jukka Järvelä

Phone: +358 (0)50 553 8990

 

About Bexmarilimab

Bexmarilimab is Faron's wholly owned, investigational immunotherapy designed
to overcome resistance to existing treatments and optimize clinical outcomes,
by targeting myeloid cell function and igniting the immune system.
Bexmarilimab binds to Clever-1, an immunosuppressive receptor found on
macrophages leading to tumor growth and metastases (i.e. helps cancer evade
the immune system). By targeting the Clever-1 receptor on macrophages,
bexmarilimab alters the tumor microenvironment, reprogramming macrophages from
an immunosuppressive (M2) state to an immunostimulatory (M1) one, upregulating
interferon production and priming the immune system to attack tumors and
sensitizing cancer cells to standard of care.

 

About BEXMAB

The BEXMAB study is a first-in-human, open-label Phase I/II clinical trial
investigating bexmarilimab in combination with standard of care (SoC) in the
aggressive hematological malignancies of acute myeloid leukemia (AML) and
myelodysplastic syndrome (MDS). The primary objective is to determine the
safety and tolerability of bexmarilimab in combination with SoC (azacitidine)
treatment and to identify the recommended Phase II dose. Directly targeting
Clever-1 could limit the replication capacity of cancer cells, increase
antigen presentation, ignite an immune response, and allow current treatments
to be more effective. Clever-1 is highly expressed in both AML and MDS and
associated with therapy resistance, limited T cell activation and poor
outcomes.

 

About Faron Pharmaceuticals Ltd.

Faron (AIM: FARN, First North: FARON) is a global, clinical-stage
biopharmaceutical company, focused on tackling cancers via novel
immunotherapies. Its mission is to bring the promise of immunotherapy to a
broader population by uncovering novel ways to control and harness the power
of the immune system. The Company's lead asset is bexmarilimab, a novel
anti-Clever-1 humanized antibody, with the potential to remove
immunosuppression of cancers through targeting myeloid cell function.
Bexmarilimab is being investigated in Phase I/II clinical trials as a
potential therapy for patients with hematological cancers in combination with
other standard treatments. Further information is available at www.faron.com
(https://eur01.safelinks.protection.outlook.com/?url=http%3A%2F%2Fwww.faron.com%2F&data=05%7C01%7C%7Ca4ae0afa96854c5c5f2a08db771ae20d%7Ca2d9b7a432f64a96b03727499230d5fd%7C1%7C0%7C638234729855975666%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000%7C%7C%7C&sdata=%2FNadoN9wXIGZtfCkFVuLSTXPpNg3%2BBXoRfIQaIPce6k%3D&reserved=0)
.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAPBMATMTAMBLJ